Clinical trials: Encephalitis
Japanese Encephalitis, Hepatitis A
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.
- Trial name
- NCT00621764
- Testing
- Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
- Where
- 3 sites in Thailand
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Stroke, Ischemic, Inflammatory Response
TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
DESIGN: exploratory, prospective, natural history, imaging cohort study BACKGROUND: Stroke causes a strong inflammatory response in the brain which is thought to contribute to permanent brain damage in stroke patients.
- Conditions
- Stroke, Ischemic, Inflammatory Response, Stroke, Acute
- Trial name
- NCT03662750
- Testing
- Brain Imaging
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Japanese Encephalitis
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years
- Trial name
- NCT00605085
- Testing
- Japanese Encephalitis purified inactivated vaccine (IC51)
- Volunteers
- 2,675 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose
- Trial name
- NCT00595270
- Testing
- IC51
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains…
- Trial name
- NCT00319592
- Testing
- ChimeriVax™-JE vaccine, JE-VAX® vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis, Hepatitis A
Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi…
- Trial name
- NCT00735644
- Testing
- Japanese encephalitis vaccine, Japanese encephalitis vaccine (Acambis), Hepatitis A vaccine
- Where
- 8 sites in Philippines, Thailand
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
West Nile Neuroinvasive Disease, West Nile Virus Infection
Treatment of West Nile Virus With MGAWN1
This study will test a drug called MGAWN1 for the treatment of West Nile infections.
- Conditions
- West Nile Neuroinvasive Disease, West Nile Virus Infection, Encephalitis, Meningitis
- Trial name
- PARADIGM (NCT00927953)
- Testing
- MGAWN1
- Volunteers
- 13 people
- Sponsor
- MacroGenics
Japanese Encephalitis
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
- Trial name
- NCT00594958
- Testing
- IC51
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
This is a randomized, open-label Phase 3 study including children aged >9 months to <17 years and 7 months who have been vaccinated with IXIARO in study IC51-323.
- Trial name
- NCT01296360
- Testing
- IXIARO
- Where
- 3 sites in Philippines
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Virus Diseases
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after first booster with Tick-Borne Encephalitis (TBE) vaccine.
- Trial name
- NCT03294135
- Testing
- Encepur Adults
- Where
- Czechia
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tick-Borne Encephalitis, Encephalitis, Tick-Borne
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
This was an open label trial of a non-US licensed vaccine for tick-borne encephalitis. The vaccine was licensed by Baxter, and now following an acquisition by Pfizer Inc in Vienna, Austria since 2001, and has an extensive safety…
- Conditions
- Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus
- Trial name
- TBEV (NCT01031537)
- Testing
- FSME-IMMUN 0.5ml Baxter
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Japanese Encephalitis
Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
This randomised, double-blind study is to be conducted on 96 subjects at multiple sites in India. Subjects will be enrolled by age group and randomised to either ChimeriVax™-JE (JE-CV) or JE Mouse Brain Derived Vaccine (JE-MBDV).
- Trial name
- NCT00441259
- Testing
- ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine
- Where
- 3 sites in India
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sanofi
Vaccine Responsiveness in Allergy, Vaccine Responsiveness During Allergy De-sensitization Treatment
TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Allergic patients especially those undergoing de-sensitization treatment have an altered immune responsiveness. The investigators aim to find out whether this influences immune responses to primary and booster vaccinations.
- Trial name
- NCT02511535
- Testing
- TBE booster vaccination
- Where
- Austria
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Japanese Encephalitis
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged > or = 18 years
- Trial name
- NCT00595790
- Testing
- IC51
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.
- Trial name
- NCT00595309
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Japanese B
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
The previously conducted JEV01 study looked at the immunogenicity and safety of the concurrent administration of Japanese Live Attenuated SA 14-14-2 and measles vaccines at the one month post vaccination time point.
- Trial name
- NCT00412516
- Testing
- Live attenuated SA 14-14-2 vaccine
- Where
- Philippines
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- PATH
Autoimmune Encephalitis
Efficacy of Ocrelizumab in Autoimmune Encephalitis
This pilot study is a randomized, double-blind, placebo controlled study of the efficacy of ocrelizumab in autoimmune encephalitis. Subjects with new diagnosis of autoimmune encephalitis will be invited to enroll in this study.
- Trial name
- NCT03835728
- Testing
- Ocrelizumab, Saline
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Texas Southwestern Medical Center
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University